6505--Levetiracetam Tablets

The Department of Veterans Affairs (VA) National Acquisition Center intends to issue an unrestricted Request for Proposal (RFP) 36E79726R0001 for Levetiracetam Tablets. This procurement aims to secure an uninterrupted supply for the VA (including CMOPs and SVH), Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). One contract will be awarded for a one-year base period with four one-year option periods. Offerors must provide drugs with unique NDC numbers and specific packaging requirements, including safety-caps and bottle dimensions. The solicitation, with NAICS code 325412, will be issued electronically around November 10, 2025, with a tentative closing date of November 24, 2025. All updates will be available on sam.gov. Estimated annual usages for various Levetiracetam tablet strengths are detailed. The point of contact is Youlanda Duggar.

This document is an amendment (0001) to solicitation 36E79726R0001, issued by the Department of Veterans Affairs, OPAL / National Acquisition Center. The primary purpose of this amendment is to extend the due date and time for receiving offers for Levetiracetam Tablets. The new deadline for offer submissions has been extended from November 26, 2025, to December 3, 2025, at 2:30 PM Central Time. All other terms and conditions of the original solicitation remain unchanged. Offerors are required to acknowledge receipt of this amendment by including a completed and signed copy with their proposal. The amendment emphasizes that failure to acknowledge receipt prior to the specified deadline may result in the rejection of an offer.

This government solicitation, 36E79726R0001, is issued by the Department of Veterans Affairs (VA) to establish a supply source for Levetiracetam tablets. The contract will cover a base year and four one-year option periods, with one award made in aggregate for seven line items of various strengths and bottle sizes. Offerors must submit prices for all line items across all years, including a 0.5% Cost Recovery Fee. The contract involves distribution through VA and DoD Pharmaceutical Prime Vendor (PPV) Programs, requiring the awarded contractor to establish business-to-business agreements with PPVs. Key requirements include product registration with FDA, First Databank, Medispan, and Cerner Multum, adherence to packaging and barcoding standards (including DSCSA), and possession of necessary FDA drug applications. The solicitation also details procedures for backorders, recalls, and compliance with manufacturing facility cGMP status. Sales reports and Cost Recovery Fee payments are due quarterly. Covered drugs must meet 38 U.S.C. § 8126 requirements and offerors must have existing Master Agreements and Pharmaceutical Pricing Agreements with VA FSS.